<DOC>
	<DOCNO>NCT01997333</DOCNO>
	<brief_summary>The main purpose study see whether CDX-011 ( glembatumumab vedotin , antibody-drug conjugate ) effective treat patient advance Triple-Negative Breast Cancer ( TNBC ) , whose tumor cell make protein call glycoprotein NMB ( gpNMB ) , CDX-011 bind . The study also characterize safety CDX-011 treatment patient population .</brief_summary>
	<brief_title>Study Glembatumumab Vedotin ( CDX-011 ) Patients With Metastatic , gpNMB Over-Expressing , Triple Negative Breast Cancer</brief_title>
	<detailed_description>CDX-011 consist antibody attached drug , monomethyl auristatin E ( MMAE ) , kill cancer cell . The antibody deliver drug cancer cell attach protein call glycoprotein NMB ( gpNMB ) express cancer cell . The MMAE release inside cell , interfere cell growth may lead cell death . This study examine efficacy safety CDX-011 patient advance TNBC make gpNMB protein . The effect CDX-011 compare treatment capecitabine . Eligible patient enroll study randomly assign ( chance ) receive treatment CDX-011 capecitabine . For every three patient enrol , two receive CDX-011 one receive treatment capecitabine . All patient enrol study closely monitored determine cancer respond treatment side effect may occur .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Among criterion , patient must meet following condition eligible study : 1 . Diagnosed metastatic ( i.e. , cancer spread ) TNBC minimal expression estrogen progesterone receptor ( ER/PR ) &lt; 10 % cell positive immunohistochemistry HER 2 stain 0 1+ IHC copy number &lt; 4.0 signals/cell 2 . Documented progression disease base radiographic , clinical pathologic assessment subsequent last anticancer regimen receive . 3 . Breast cancer tumor confirm express gpNMB . This determine submit tissue sample advance ( locally advanced/recurrent metastatic ) disease set central laboratory analysis . 4 . Received two prior chemotherapy treatment advance ( locally advanced/recurrent metastatic ) breast cancer . 5 . Prior chemotherapy treatment must contain anthracycline ( e.g . doxorubicin Doxil ) clinically indicate taxane ( eg : Taxol ) . 6 . ECOG performance status 0 1 . 7 . Adequate bone marrow , liver renal function . Exclusion : Among criterion , patient meet follow condition NOT eligible study : 1 . Progression/recurrence breast cancer within 3 month completion neoadjuvant adjuvant chemotherapy . 2 . Ongoing neuropathy chemotherapy radiationrelated toxicity moderate ( Grade 2 ) bad severity . 3 . Known brain metastasis , unless previously treat asymptomatic 2 month progressive size number 2 month . 4 . Significant cardiovascular disease . 5 . Previously receive capecitabine discontinue due progression intolerance ; previously receive CDX011 MMAE contain agent . 6 . Active systemic infection require treatment . Infection control oral therapy exclusionary . 7 . Chronic use systemic corticosteroid .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Metastatic Breast Cancer</keyword>
	<keyword>Locally advanced breast cancer</keyword>
	<keyword>Breast cancer</keyword>
	<keyword>Triple negative</keyword>
	<keyword>Estrogen</keyword>
	<keyword>Progesterone</keyword>
	<keyword>HER2 receptor</keyword>
	<keyword>Targeted treatment breast cancer</keyword>
	<keyword>Antibody-drug-conjugate</keyword>
	<keyword>Breast Neoplasms</keyword>
	<keyword>CDX-011</keyword>
	<keyword>gpNMB</keyword>
	<keyword>METRIC</keyword>
	<keyword>Glembatumumab vedotin</keyword>
	<keyword>Triple Negative Breast Cancer</keyword>
	<keyword>TNBC</keyword>
</DOC>